je.st
news
Tag: merck
Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubists 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020
2015-02-23 23:03:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced the results of its tender offer (the Convertible Notes Tender Offer) pursuant to which each holder of Cubists 2.50% Convertible Senior Notes due 2017 (the 2017 Convertible Notes), 1.125% Convertible Senior Notes due 2018 (the 2018 Convertible Notes) and 1.875% Convertible Senior Notes due 2020 (the 2020 Convertible Notes and together with th Language: English Contact: MerckMedia:Lainie Keller, (908) 236-5036Steve Cragle, (908) 740-1801orInvestor:Joe Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Bets $450M on 'Old School' Biotech From NGM
2015-02-23 16:03:03| Biotech - Topix.net
Luke Timmerman is a journalist specializing in biotechnology. He is the founder and editor of the Timmerman Report, a subscription publication for biotech insiders.
Tags: school
biotech
bets
merck
NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
2015-02-23 13:00:00| Merck.com - Corporate News
Dateline City: SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J. Partnership Combines NGMs Unique Biology-focused Research Platform with Mercks Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)-- NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestor Relations:Justin Holko, 908-740-1879orNGM BiopharmaceuticalsMedia Relations:Tony Plohoros, 908-940-01356 Degreestplohoros@6degreespr.comorInvestor Relations:Beth DelGiacco, 212-362-1200Stern Investor Relationsbeth@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: develop
broad
discover
collaboration
Former Merck Analyst Pleads Guilty to Insider Trading Charges
2015-02-20 19:39:31| Biotech - Topix.net
A former financial analyst for pharmaceutical giant Merck & Co. Inc. this week pleaded guilty to charges related to insider trading, authorities said.
Tags: charges
trading
insider
analyst
Merck senior management tried to pay off its own vaccine scientists...
2015-02-08 04:59:03| Biotech - Topix.net
As the corporate media desperately attempts to dupe as many people as possible into getting MMR vaccines for the protection of "the children," uncovered court documents revealing major vaccine fraud at Merck & Co., the multinational drug company that produces MMR vaccines for the U.S. market, are only getting the attention they deserve from the alternative media. Back in 2010, two former Merck scientists, repulsed by what they saw taking place at the highest levels of the company, filed a False Claims Act in the U.S. District Court for the Eastern District of Pennsylvania.
Tags: management
pay
senior
scientists
Sites : [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] next »